SCHEMBL4050545

SCHEMBL4050545

CCn1nc(-c2cccs2)c(C(=O)OCOC(=O)OC(C)C)c(Nc2cncc3ccccc23)c1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 1/20 0.38
PDE4B Q07343 1/20 0.34
ALDH1A1 P00352 9/20 0.33
SMN1; SMN2 Q16637 7/20 0.33
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
KDM4E B2RXH2 5/20 0.32
HPGD P15428 4/20 0.32
POLB P06746 3/20 0.32
TP53 P04637 3/20 0.32
LMNA P02545 2/20 0.32
TSHR P16473 2/20 0.32
HSD17B10 Q99714 2/20 0.32
MEN1 O00255 4/20 0.32
KMT2A Q03164 4/20 0.32
NPSR1 Q6W5P4 3/20 0.32
MAPT P10636 3/20 0.32
HIF1A Q16665 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4370564 0.97 ADORA1 (0.36) ADORA1PDE4BALDH1A1SMN1; SMN2NPC1
SCHEMBL4059427 0.90 ADORA1 (0.41) ADORA1PDE4BALDH1A1SMN1; SMN2NPC1
SCHEMBL4053146 0.89 ADORA1 (0.43) ADORA1PDE4BALDH1A1SMN1; SMN2NPC1
SCHEMBL4052008 0.89 PDE4B (0.45) PDE4BSMN1; SMN2POLBTP53TSHR
SCHEMBL4049939 0.87 ADORA1 (0.36) ADORA1PDE4BALDH1A1SMN1; SMN2NPC1
SCHEMBL4054456 0.87 HPGD (0.38) ADORA1PDE4BALDH1A1SMN1; SMN2NPC1
SCHEMBL4052382 0.86 ADORA1 (0.40) ADORA1PDE4BALDH1A1SMN1; SMN2NPC1
SCHEMBL4057121 0.86 ADORA1 (0.40) ADORA1PDE4BALDH1A1SMN1; SMN2NPC1
SCHEMBL4051228 0.86 ADORA1 (0.40) ADORA1ALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL5336868 0.84 MAPK1 (0.34) ADORA1PDE4BALDH1A1SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090029996-A1 phosphodiesterase enzyme inhibitor; 4-[(3-chlorophenyl)amino]-2-ethyl-5-(1-hydroxyethyl)-6-phenylpyridazin-3(2H)-one; potent antiinflammatory agent; asthma, atopic dermatitis, psoriasis, chronic obstructive pulmonary disease, rheumatoid arthritis, irritable bowel disease LABORATORIOS ALMIRALL, S.A. (ES) 2009-01-29 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090029996-A1 phosphodiesterase enzyme inhibitor; 4-[(3-chlorophenyl)amino]-2-ethyl-5-(1-hydroxyethyl)-6-phenylpyridazin-3(2H)-one; potent antiinflammatory agent; asthma, atopic dermatitis, psoriasis, chronic obstructive pulmonary disease, rheumatoid arthritis, irritable bowel disease PDE12, PDE4A, PDE4B ADORA1 311/4885PDE4B 3/4885ALDH1A1 324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.